Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Oncology

Reading Your "Scorecard": Decoding CML Lab Reports

At a Glance

CML lab reports track your treatment progress using the RT-PCR test to measure BCR-ABL1 gene levels. Results are reported on an International Scale (IS). The primary goal is to lower these levels, measured in log reductions, to achieve a Major Molecular Response (0.1% or lower).

Your lab reports are your most powerful tools for tracking how well your treatment is working. While they can look like a wall of confusing numbers and codes, they follow a very specific structure. Learning to read these reports allows you to see the “scorecard” of your battle against CML.

The “Completeness Checklist”

Every comprehensive CML monitoring report should include these key elements to give your doctor a full picture of your health:

  • The Test Type: Clearly labeled as RT-qPCR (for tracking levels), FISH, or Cytogenetics/Karyotype (for identifying the chromosome) [1][2].
  • The Target: Usually listed as BCR-ABL1 or p210 (the most common type of CML protein) [3].
  • The Result: Expressed as a percentage (e.g., 0.1%) or a scientific number [4].
  • The Control Gene: A secondary gene (like ABL1 or GUSB) measured to prove the blood sample was high-quality enough to get an accurate reading [4].
  • The International Scale (IS): A note confirming the result was converted to the global standard [4][5].

Bone Marrow vs. Blood Draw

When confirming diagnosis and monitoring progress, doctors use different types of tests:

  1. G-banded Karyotyping: This requires a bone marrow biopsy. Doctors look through a microscope at your marrow cells to see if the physical swap of chromosomes 9 and 22 is visible [3][6]. It’s often done at diagnosis to look for other chromosomal changes [7].
  2. RT-PCR (Reverse-Transcription Polymerase Chain Reaction): This is the most sensitive test. The good news is that, unlike karyotyping, this test can usually be done with a standard peripheral blood draw from your arm [1][8]. Once you start treatment, this simple blood draw becomes your primary “scorecard” to see how well the medicine is working [9][4].

Understanding the International Scale (IS)

In the past, different labs used different scoring systems, making it impossible to compare results. Today, labs use the International Scale (IS). This scale uses a “baseline” (100%) representing the average amount of BCR-ABL1 in a patient at the time of diagnosis [4][5].

As you take your medication, your goal is to drive that percentage down. Doctors measure this progress in log reductions (powers of 10) [4][10]:

  • 10% (1-log reduction): Often called Early Molecular Response (EMR). Achieving this by the 3-month mark is a very strong sign that your treatment is working well [11][12].
  • 1% (2-log reduction): Your “leukemia load” has dropped 100 times lower than at diagnosis.
  • 0.1% (3-log reduction): This is Major Molecular Response (MMR). At this level, your risk of the disease progressing becomes extremely low [11][13].
  • 0.01% or lower (4-log reduction or more): This is Deep Molecular Response (DMR). This is the level required before a patient and doctor can even begin discussing the possibility of stopping medication in the future [14][9]. Learn more about this goal in The Long Game.

Decoding Common Lab Terms

  • Cytogenetic Response: This refers to what is visible under a microscope. A “Complete Cytogenetic Response” (CCyR) means the Philadelphia chromosome can no longer be seen in your bone marrow cells [1].
  • Molecular Response (MR): This refers to the much more sensitive PCR results. You might see terms like MR4 (0.01%) or MR4.5 (0.0032%), which describe exactly how many “logs” the leukemia has dropped [11][15].
  • Not Detected / Undetectable: This does not mean the CML is gone forever; it simply means the amount of BCR-ABL1 is so small that the current test cannot find it. This is the highest level of response [16].

By keeping a log of these percentages, you can visualize your progress. Many patients find it helpful to graph their BCR-ABL1 levels over time to see the downward trend toward their molecular goals.

Common questions in this guide

What does the International Scale (IS) mean on my CML lab report?
The International Scale is a standardized scoring system used to report BCR-ABL1 levels. It uses a 100% baseline representing the average amount of the gene at diagnosis, allowing doctors to consistently track how well your treatment is working over time.
What is a Major Molecular Response (MMR) in CML?
Major Molecular Response, or MMR, means your BCR-ABL1 level has dropped to 0.1% or lower on the International Scale. Achieving this level is an important milestone because it indicates your risk of the disease progressing is extremely low.
Does an 'undetectable' result mean my CML is completely cured?
No, an undetectable result does not mean the leukemia is permanently gone. It simply means the amount of the BCR-ABL1 gene in your blood is so small that current PCR tests cannot find it, which is the highest level of treatment response.
What is the difference between a bone marrow biopsy and a blood draw for CML testing?
A bone marrow biopsy is typically used at diagnosis to physically look at chromosomes under a microscope. Once treatment begins, doctors usually use a simple blood draw for an RT-PCR test, which is highly sensitive and accurately measures your leukemia levels.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my BCR-ABL1 result being reported on the International Scale (IS)?
  2. 2.What 'control gene' (like ABL1 or GUSB) was used to ensure the sample quality of my PCR test?
  3. 3.Has my BCR-ABL1 level achieved a 'Major Molecular Response' (MMR) or 'Deep Molecular Response' (DMR) yet?
  4. 4.What was the total number of cells analyzed in my FISH or Karyotype report, and were there any 'additional chromosomal abnormalities' besides the Philadelphia chromosome?
  5. 5.How many 'logs' has my BCR-ABL1 level dropped since my very first test?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    A rare e9a1 BCR-ABL1 fusion transcript in chronic myeloid leukemia.

    Miao Y, Huang Y, Feng C, et al.

    International journal of laboratory hematology 2017; (39(1)):e14-e16 doi:10.1111/ijlh.12573.

    PMID: 27863067
  2. 2

    Comparative Analysis of Fluorescence In Situ Hybridization and Real Time Polymerase Chain Reaction in Diagnosis of Chronic Myeloid Leukemia.

    Ali J, Khan SA, Rauf S-, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2017; (27(1)):26-29 doi:2516.

    PMID: 28292364
  3. 3

    Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.

    Arun AK, Senthamizhselvi A, Mani S, et al.

    International journal of laboratory hematology 2017; (39(3)):235-242 doi:10.1111/ijlh.12616.

    PMID: 28035733
  4. 4

    Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.

    Schäfer V, White HE, Gerrard G, et al.

    Journal of cancer research and clinical oncology 2021; (147(10)):3081-3089 doi:10.1007/s00432-021-03569-8.

    PMID: 33677711
  5. 5

    Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.

    Brown JT, Beldorth IJ, Laosinchai-Wolf W, et al.

    The Journal of molecular diagnostics : JMD 2019; (21(4)):718-733 doi:10.1016/j.jmoldx.2019.03.002.

    PMID: 31026597
  6. 6

    Very Rare Coexistence of Inversion (16), Trisomy 8, and t(9;22) in a Chronic Myeloid Leukemia Patient Progressing to Myeloblastic Crisis.

    Patel DM, Trivedi PJ, Barad KD

    Journal of the Association of Genetic Technologists 2025; (51(2)):75-78.

    PMID: 40450873
  7. 7

    [Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].

    Guan Y, Liu Q, Huang DP, He HS

    Zhongguo shi yan xue ye xue za zhi 2020; (28(5)):1528-1533 doi:10.19746/j.cnki.issn.1009-2137.2020.05.017.

    PMID: 33067949
  8. 8

    Identification of rare atypical BCR-ABL1 transcript: A case report.

    Saha J, Gopinath V, Nair CK, Roshan D

    Indian journal of pathology & microbiology 2023; (66(3)):624-626 doi:10.4103/ijpm.ijpm_715_21.

    PMID: 37530356
  9. 9

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Hochhaus A, Baccarani M, Silver RT, et al.

    Leukemia 2020; (34(4)):966-984 doi:10.1038/s41375-020-0776-2.

    PMID: 32127639
  10. 10

    Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.

    Takahashi N, Kameoka Y, Onizuka M, et al.

    Cancer medicine 2023; (12(4)):4250-4258 doi:10.1002/cam4.5292.

    PMID: 36151699
  11. 11

    Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels

    Ceran F, Akıncı S, Uçar MA, et al.

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2022; (39(3)):196-203 doi:10.4274/tjh.galenos.2022.2022-0024.

    PMID: 35620443
  12. 12

    Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.

    Zhang J, Wang Y, Wang J, et al.

    Blood cancer journal 2018; (8(7)):61 doi:10.1038/s41408-018-0093-4.

    PMID: 29915172
  13. 13

    Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

    Garcia-Gutierrez V, Huang F, Ashaye A, et al.

    Frontiers in oncology 2024; (14()):1455378 doi:10.3389/fonc.2024.1455378.

    PMID: 39634261
  14. 14

    Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

    Dragani M, Rege-Cambrin G, Ferrero D, et al.

    Leukemia & lymphoma 2019; (60(13)):3330-3332 doi:10.1080/10428194.2019.1622103.

    PMID: 31161827
  15. 15

    Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.

    Nee A, Lipton JH, Kim DDH

    Leukemia & lymphoma 2022; (63(1)):162-169 doi:10.1080/10428194.2021.1961234.

    PMID: 34379028
  16. 16

    Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.

    Dulucq S, Nicolini FE, Rea D, et al.

    Haematologica 2022; (107(12)):2859-2869 doi:10.3324/haematol.2022.280811.

    PMID: 35615931

This page explains CML lab report terminology for educational purposes only. Your hematologist or oncologist is the best source for interpreting your specific test results and treatment progress.

Get notified when new evidence is published on Chronic myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.